Variable | Base Case | Range | Reference |
---|---|---|---|
Annual risk of CBC | Â | Â | [13] |
 No family history of breast cancer | 0.0047 | 0.0041–0.0052 |  |
 Second-degree relative only | 0.0061 | 0.0470–0.0900 |  |
 First-degree relative, unilateral | 0.0090 | 0.0063–0.0121 |  |
 First-degree relative, bilateral | 0.0168 | 0.0088–0.0330 |  |
 BRCA 1/2 mutation carriers | 0.0184 | 0.0160–0.0213 |  |
 ER-negative/ER-positive risk ratio | 1.25 | 1.10–2.00 | |
 CBC risk reduction after CPM | 0.95 | 0.75–1.00 | |
Risk of developing CBC stage I-IV | Â | Â | [21] |
 Stage I | 0.66 |  |  |
 Stage II | 0.25 |  |  |
 Stage III | 0.05 |  |  |
 Stage IV | 0.04 |  |  |
10-year disease-specific risk of dying | Â | Â | [7] |
 Stage I | 0.018 |  |  |
 Stage II | 0.231 |  |  |
 Stage III | 0.592 |  |  |
 Stage IV | 0.911 |  |  |
Risk of dying of other causes | Age specific | Â | [23] |
 |  |  | |
 First year after treatment |  |  |  |
  CPM | 0.70 | 0.41–0.95 |  |
  No CPM | 0.90 | 0.87–1.00 |  |
 No CBC |  |  |  |
  Years 2-5 | 0.79 | 0.45–1.00 |  |
  Year 6 and beyond | 0.84 | 0.77–1.00 |  |
 CBC |  |  |  |
  New CBC | 0.73 | 0.58–1.00 |  |
  Years 2-5 | 0.79 | 0.45–1.00 |  |
  Year 6 and beyond | 0.84 | 0.77–1.00 |  |
  Long-term survivor | 0.84 | 0.77–1.00 |  |